Results 121 to 130 of about 78,835 (252)

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu   +7 more
wiley   +1 more source

Gabapentinoids‐duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Chronic pain represents a complex debilitating condition that extends beyond the protective function of physiological pain, often persisting as an independent disease entity. Chronic primary and secondary pain syndromes reflect a multifaceted continuum involving nociceptive, neuropathic and nociplastic mechanisms.
Stefania Nobili   +6 more
wiley   +1 more source

A Clinical-Metabolic Prediction Model for Suicidal Behaviors Risk Stratification in First-Admission Major Depressive Disorder: A Cross-Sectional Analysis

open access: yesNeuropsychiatric Disease and Treatment
Lei Geng,1,2 Sheng Zhang,1,2 Jun Yan,1,2 Runlan Wang1,2 1Department of Psychiatry, Wuhan Mental Health Center, Wuhan, People’s Republic of China; 2Department of Psychiatry, Wuhan Hospital for Psychotherapy, Wuhan, People’s Republic of ChinaCorrespondence:
Geng L, Zhang S, Yan J, Wang R
doaj  

Relationships among nitrous oxide exposure, neurological injury and biomarkers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Recreational nitrous oxide (N2O) misuse is an increasing public health problem associated with functional cobalamin (B12) deficiency and severe neurological complications. Despite growing recognition of its harms, the dose–response relationship and clinical value of biomarkers remain unclear.
Laxna Bhujel   +6 more
wiley   +1 more source

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask   +6 more
wiley   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba   +2 more
wiley   +1 more source

Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire   +3 more
wiley   +1 more source

Editorial: Ketogenic metabolic therapy as a treatment for mental health disorders

open access: yesFrontiers in Nutrition
Georgia Ede   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy